Tag: Mortality

According to the PINETREE trial, a 3-day course of intravenous remdesivir reduced the risk of hospitalization or death by 87% in high-risk, non-hospitalized COVID-19 patients compared to placebo. This impressive statistic highlights that answering 'What is the success rate of remdesivir?' is highly dependent on the specific clinical context, including disease severity and timing of administration.

According to the American Diabetes Association (ADA), metformin is the recommended first-line therapy for type 2 diabetes. Several key advantages explain why metformin is favored over sulfonylureas, highlighting what are four benefits metformin has over the sulfonylureas.

In 2017–2019, approximately 65% of women in the U.S. aged 15–49 used contraception [1.7.1]. The pivotal question, 'Does birth control affect lifespan?', reveals a complex balance of protective benefits and potential risks that impact long-term health and mortality.

Fatal adverse events, though rare, are a known risk of rituximab treatment, with some studies showing mortality rates around 0.5% to 3% depending on the patient population [1.3.2, 1.3.1]. This article analyzes the data regarding the query, 'How many people have died from rituximab?', by examining the specific causes and risk factors.

According to a 2025 analysis published in *PLOS ONE*, overall antidepressant use in individuals with depression showed no statistically significant association with all-cause mortality after controlling for confounding factors, though initial unadjusted rates appeared higher. However, the question "Do antidepressants affect lifespan?" remains complex, with conflicting studies and a critical need to differentiate between the effects of medication and the profound impact of the underlying illness itself.